Arrowhead Pharmaceuticals Reports Fiscal 2026 Results (Period Ended Jun 30, 2026)

What Happened

• Arrowhead Pharmaceuticals, Inc. (ARWR) filed a Current Report on Form 8-K on August 4, 2026 (Item 2.02) announcing and commenting on its fiscal 2026 financial results for the period ended June 30, 2026.
• The company furnished a press release with the results as Exhibit 99.1.

Key Details

• Filing date: August 4, 2026.
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (fiscal 2026 results for period ended June 30, 2026).
• Press release describing the results was furnished as Exhibit 99.1.
• Per General Instruction B.2 of Form 8-K, the information in this filing (including Exhibit 99.1) is furnished — not “filed” — and therefore is not subject to Section 18 liability or automatically incorporated by reference into other filings.

Why It Matters

• This 8-K signals Arrowhead has publicly released its most recent quarterly/fiscal operating and financial results; the press release will contain the specific revenue, expense, and other metrics investors use to assess performance.
• Because the document is furnished (not filed), it notifies investors of the results but carries different legal treatment than a “filed” disclosure; investors should review the press release and any accompanying financial statements or investor presentation for the detailed numbers and context before making decisions.